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Background: Mutations in ATP-binding-cassette-member A3 (ABCA3) are related to severe chronic lung disease in
neonates and children, but frequency of chronic lung disease due to ABCA3 mutations in the general population is
unknown. We tested the hypothesis that individuals heterozygous for ABCA3 mutations have reduced lung function
and increased risk of COPD in the general population.
Methods: We screened 760 individuals with extreme pulmonary phenotypes and identified three novel
(H86Y, A320T, A1086D) and four previously described mutations (E292V, P766S, S1262G, R1474W) in the ABCA3
gene. We genotyped the entire Copenhagen City Heart study (n = 10,604) to assess the clinical importance of these
mutations. To validate our findings we genotyped an additional 54,395 individuals from the Copenhagen General
Population Study.
Results: In the Copenhagen City Heart Study individuals heterozygous for E292V had 5% reduced FEV1 % predicted
compared with noncarriers (t-test: p = 0.008), and an increased odds ratio for COPD of 1.9
(95% CI: 1.1-3.1). In contrast, the A1086D mutation was associated with increased FEV1 % predicted (p = 0.03). None
of the other ABCA3 mutations associated with lung function or COPD risk in the Copenhagen City Heart Study. In
the larger Copenhagen General Population Study, and in the two studies combined, E292V heterozygotes did not
have reduced lung function or increased risk of COPD (p = 0.11-0.98), while this was the case for the positive
controls, surfactant protein-B 121ins2 heterozygotes and α1-antitrypsin ZZ homozygotes.
Conclusion: Our results indicate that partially reduced ABCA3 activity due to E292V is not a major risk factor for
reduced lung function and COPD in the general population. This is an important finding as 1.3% in the Danish
population has partially reduced ABCA3 function due to E292V.
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Pulmonary surfactant is a thin lipid membrane that cov-
ers the alveoli and lowers surface tension, thereby pre-
venting collapse of the alveoli at end-expiration.
Pulmonary surfactant consists of phospholipids and pro-
teins mainly synthesized by alveolar type II cells. The
pulmonary surfactant is assembled and stored in the al-
veolar type II cell in lamellar bodies, which are subse-
quently released to the alveoli by exocytosis [1,2]. The
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distribution, and reproduction in any medium(ABCA3) is expressed in the limiting membrane of the
lamellar bodies. Here it transports several types of lipids
making it essential for correct assembly of pulmonary
surfactant in the alveolar type II cell [3,4].
Recessive mutations in the ABCA3 gene have been
related to deficiency of pulmonary surfactant leading to
neonatal lung disease and chronic lung disease in chil-
dren [3,5]; however, frequency of chronic lung disease
due to ABCA3 mutations in the general population is
unknown. At present more than 150 disease-associated
mutations have been identified [3]. A relatively common
mutation in ABCA3, E292V, is associated with partially
impaired ABCA3 function [6] and with milder chronic
lung disease in childhood [3,6]. This mutation is situated
in a conserved intracellular loop of ABCA3 with import-
ance for ATP hydrolysis activity. The E292V mutationCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Bækvad-Hansen et al. Respiratory Research 2012, 13:67 Page 2 of 9
http://respiratory-research.com/content/13/1/67has been found in about 0.3-0.4% of individuals in a het-
erogeneous US population [7] and may affect both het-
erozygous [8,9] and compound heterozygous carriers
[8,10]. Because mice with 50% reduced ABCA3 die from
respiratory distress or develop emphysema [11], indivi-
duals heterozygous for ABCA3 variants may also be at
increased risk of emphysema/COPD. Given this, ABCA3
variants, and in particular E292V, could play an import-
ant role on development of common pulmonary disor-
ders in the general population.
In this study we hypothesise that individuals heterozy-
gous for ABCA3 variants have reduced lung function
and increased risk of COPD in the general population.
To test this, we first screened 760 adults with extreme
lung phenotypes in the Copenhagen City Heart Study to
identify ABCA3 variants that could potentially be asso-
ciated with lung disease in the general population. Fol-
lowing this we genotyped the entire Copenhagen City
Heart Study (n = 10,604) for variants identified by the
initial screening to test whether ABCA3 heterozygotes
have reduced lung function or increased risk of COPD.
When a positive association was observed, we genotyped
an additional population-based study, the Copenhagen
General Population Study (n = 54,395) in an attempt to
reproduce the finding. As positive controls for reduced
lung function due to genetic background, we used
surfactant protein-B 121ins2 heterozygosity and α1-
antitrypsin ZZ homozygosity [12,13].Methods
Subjects
The Copenhagen City Heart Study is a prospective gen-
eral population study of individuals selected based on
the Central Population Register Code to reflect the adult
Danish population aged 20-80+ years [13,14]. The Co-
penhagen City Heart Study was initiated in 1976–1978
with follow-up examinations in 1981–1983, 1991–1994,
and 2001–2003. DNA was isolated from participants
attending the 1991–1994 (n = 9252) and/or 2001–2003
examinations (additional n = 1352).
The Copenhagen General Population Study is an on-
going population-based cohort study initiated in 2003
[12,15]. At the time of genotyping for the present study,
54,395 individuals had been included. Participants were
selected based on the Central Population Register Code
to reflect the adult Danish population aged 20-80+ years.
Participants are recruited from a different part of Co-
penhagen than the Copenhagen City Heart Study and
there is no overlap of individuals between the two stud-
ies. The studies were approved by the Danish ethical
committees: Nos. KF-100.2039/91 and H-KF-01-421/94.
All participants gave written informed consent and all
participants were whites of Danish descent.Pulmonary endpoints
FEV1 and FVC were determined with a dry wedge spir-
ometer (Vitalograph; Maids Moreton, Buckinghamshire,
UK) in the Copenhagen City Heart Study, and with
EsyOne Spirometer (ndd Medizintechnik, Zurich, Switz-
erland) in the Copenhagen General Population Study.
Algorithms for calculation of FEV1 % predicted and FVC
% predicted were made using multiple regressions with
age and height as covariates on all individuals for men
and women separately. COPD was defined as FEV1/FVC
< 0.7 and FEV1 < 80% of predicted (GOLD stages 2–4)
[16]; if this definition excluded asthmatics, the results
were similar to those presented. To increase the likeli-
hood of detecting genetic variation in ABCA3 associated
with lung disease, we performed resequencing of the
ABCA3 gene in an extreme risk population in the Co-
penhagen City Heart Study (Additional file 1). The risk
population was defined as those individuals with the
earliest onset of COPD (n = 175) and asthma (n =174),
individuals with interstitial lung disease (n = 31), and
individuals with the lowest FEV1 % predicted among
non smokers (n = 118), lowest FEV1 % predicted among
smokers (n = 122), and highest FEV1 % predicted in the
population (n = 140) [17]. We ensured that there was no
overlap between the risk groups when selecting these
individuals from our database. The number of indivi-
duals selected for each extreme phenotype group was
based on our laboratory set-up consisting of two 384-
well DNA plates (4 wells were for controls). For the first
DNA plate we selected all individuals with interstitial
lung disease (n = 31). Among the remaining individuals
we ranked the patients with COPD according to age and
selected the youngest 175 individuals. We then selected
the youngest 174 individuals with asthma in the same
way making sure that there was no overlap between
individuals with interstitial lung disease, asthma, and
COPD. For the second DNA plate, we ranked the
remaining individuals according to FEV1 % predicted
and selected those 140 individuals who had the highest
FEV1 % predicted. We next selected the 122 individuals
with the lowest FEV1 % predicted among current smo-
kers and the 118 individuals with the lowest FEV1 % pre-
dicted among exsmokers and nonsmokers to fill out the
DNA plate in full.
Genetic analysis
Thirty PCR fragments were amplified, covering all 30
protein coding exons (exons 4–33) of ABCA3 and the
intron-exon boundaries. Mutational screening analysis of
the amplicons was performed by LightScanner, a high
resolution DNA melting curve analysis technique for
variant detection [18]. PCR fragments with DNA melting
curves differing from wild type control DNA were sub-
sequently sequenced. Primer sequences are listed in
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genotype the entire Copenhagen City Heart Study for
mutations identified by resequencing (Applied Biosys-
tems Inc., Foster City, CA, USA). Primers and probes
for these analyses are listed in Additional file 3. Geno-
type results were confirmed by DNA sequencing of a
subset sample. It was not possible to design TaqMan
genotyping assays for two of the mutations (A320T and
A1086D), and genotyping for these variants was instead
performed using the LightScanner (Additional file 3).
Data analysis
Statistical analyses were performed using STATA version
10.0. A two-sided P < 0.05 was considered significant.
Main effects of genotype and statistical interaction be-
tween genotype and smoking in predicting FEV1 % pre-
dicted, FVC % predicted, and FEV1/FVC were tested by
Student’s t-test or ANCOVA. Odds ratios for spirometry
defined COPD according to genotype were determined
by a logistic regression model adjusted for age, sex, and
packyears of tobacco smoked. As positive controls for
reduced lung function and increased COPD risk due to
genetic background, we used surfactant protein-B
121ins2 heterozygosity and α1-antitrypsin ZZ homozy-
gosity [12,13]. We utilized NCSS-PASS (NCSS, Kaysville,
UT, USA) to calculate the odds ratios, which we had
80% power to exclude at p-values <0.05.
Results
Clinical characteristics of the individuals with extreme
lung phenotypes are listed in Additional file 1. As
expected, individuals with early-onset COPD and inter-
stitial lung disease were older and more likely smokers
than individuals without an extreme lung phenotype,
whereas individuals with early-onset asthma were
younger and less likely smokers [17]. Individuals with
the highest or lowest FEV1 % predicted did not differ in
sex or age from those without an extreme lung
phenotype.
Genetic variation in ABCA3
Resequencing of the ABCA3 gene identified a total of 55
gene variations (Additional file 4). Of these 55 variations,
29 were in protein coding regions and 19 were non-
synonymous variants. Seven of the 19 non-synonymous
variations changed a polar to a nonpolar aminoacid or
vice versa, and thus could be of functional relevance to
ABCA3. H86Y, A320T and A1086D were novel variants,
whereas E292V, P766S, S1262G and R1474W have been
described previously. Two individuals heterozygous for
P766S and one individual heterozygous for R1474W suf-
fered from interstitial lung disease (Additional file 4).
A schematic view of the location of the seven variants
in relation to the structure of ABCA3 is presented inAdditional file 5. The seven gene variants are distributed
evenly throughout the protein and are localized to intra-
and extracellular loops, the transmembrane helix and
the conserved nucleotide binding domain 2, which is im-
portant for ABCA3 interaction with ATP [19]. We used
the sorting intolerant from tolerant (SIFT) [20] and
polymorphism phenotyping (Polyphen) [21] softwares to
predict whether any of the seven variants were likely to
have a deleterious effect on ABCA3 function. SIFT and
Polyphen both predicted E292V to be damaging, but
none of the other six mutations.
Pulmonary function by ABCA3 genotype in the
Copenhagen City Heart Study
We genotyped the entire Copenhagen City Heart Study
for all seven ABCA3 mutations changing a polar to a
nonpolar aminoacid, or vice versa. Genotype frequencies
and Hardy-Weinberg statistics are listed in Additional
file 6. All mutations were in Hardy-Weinberg equilib-
rium and minor allele frequencies varied from 0.02 % to
0.9%. We calculated D’ and R2 and found no linkage dis-
equilibrium between the seven mutations (data not
shown).
Individuals heterozygous for E292V had 5% reduced
FEV1 % predicted (t-test:p = 0.008), 3% reduced FVC %
predicted (p = 0.04) and 0.02 reduced FEV1/FVC (p =
0.03), compared with wildtypes (Figure 1). The observed
reductions in pulmonary function were almost similar in
absolute numbers to those observed for surfactant
protein-B 121ins2, a mutation which in the homozygous
state associates with a phenotype somewhat similar to
that for E292V compound heterozygosity. A 5% decrease
in FEV1 % predicted would in this study equal a 152 ml
reduction of FEV1 in a 40 year old female (height 165
cm) or a 214 ml reduction of FEV1 in a 40 year old male
(height 180 cm).
In contrast, A1086D heterozygotes had increased FEV1
% predicted (p = 0.03) and FVC % predicted (p = 0.008)
compared with wildtypes, whereas the FEV1/FVC ratio
showed no statistical significant difference (p = 0.51).
Because this result was based on a small number of het-
erozygous individuals (n = 4), it is likely that this could
be a chance finding. Furthermore, due to the improved
spirometry observed, this mutation is unlikely to cause
lung disease. Thus we did not attempt to reproduce this
association in the Copenhagen General Population
Study.
Individuals heterozygous for H86Y, A320T, P766S,
S1262G, or R1474W did not differ from wildtypes
in FEV1 % predicted, FVC % predicted or FEV1/FVC
(p≥0.19). We sought to examine whether a combination
of multiple variations in ABCA3 were associated with
reduced lung function and COPD risk; however, only a
single individual in the Copenhagen City Heart Study
60 80 100 120 60 80 100 120 0.6 0.8
Genotype N FEV1 % predicted p FVC % predicted p FEV1/FVC p
H86Y
    Wt 9801
    Het 15 0.76 0.91 0.39
E292V
    Wt 9706
    Het 110 0.008 0.04 0.03
A320T
    Wt 9803
    Het 13 0.19 0.27 0.74
P766S
    Wt 9695
    Het 121 0.65 0.42 0.55
A1086D
    Wt 9802
    Het 4 0.03 0.008 0.51
S1262G
    Wt 9802
    Het 14 0.47 0.77 0.53
R1474W    
    Wt 9636
    Het 180 0.49 0.20 0.48
SP-B121ins2
Wt 10425
    Het 21 0.67 0.68 0.10
α1-antitrypsin
    MM 8082
    ZZ 6 0.01 0.55 0.0008
Figure 1 Lung function according to ATP binding cassette member 3 (ABCA3) genotype in the Copenhagen City Heart Study. Values
are mean and standard error. P-values are by Student’s t-test. Lung function according to surfactant protein-B 121ins2 heterozygosity and α1-
antitrysin ZZ homozygosity serve as positive controls. Numbers of individuals with surfactant protein-B 121ins2 heterozygosity and α1-antitrypsin
ZZ homozygosity differ slightly from the number of individuals with ABCA3 genotypes due to different number of study subjects available for
analysis within the study period.
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iants. This individual was compound heterozygous for
P766S and S1262G and was not identified among the ex-
treme phenotypes group. This person had FEV1/FVC of
0.71 and FEV1 % predicted of 83%. If correction for
multiple comparisons was performed in Figure 1 (P <
0.05/27 comparisons = p < 0.002) only the results for
FEV1/FVC in ZZ homozygotes would be of statistical
significance.
COPD by ABCA3 genotype in the Copenhagen City Heart
Study
Individuals heterozygous for E292V had a multivariate
adjusted odds ratio for COPD of 1.9 (95% CI 1.1-3.1) com-
pared with wildtypes in the Copenhagen City Heart Study
(Figure 2). The observed risk of COPD was slightly lower
than that observed for surfactant protein-B 121ins2 hetero-
zygotes in Figure 2. For the H86Y, P766S and R1474Wmutations, risk of COPD did not deviate significantly from
1.0. This is in accordance with the results on pulmonary
function for these variants. Due to lack of events among
A320T, A1086D and S1262G heterozygotes, we were not
able to calculate risk of COPD for these variants. None of
the ABCA3 mutations associated with asthma in the Co-
penhagen City Heart Study (data not shown).
Pulmonary function and COPD by ABCA3 E292V in the
Copenhagen General Population Study
To further validate the findings for E292V, we genotyped
the Copenhagen General Population Study (n = 54,395)
for the E292V variant. The genotype distribution did not
differ from that in the Copenhagen City Heart Study
(Additional file 7). Clinical characteristics of individuals
from the Copenhagen City Heart Study and Copenhagen
General Population Study are displayed in table 1. Char-
acteristics did not differ between E292V heterozygotes
Age adjusted




    Wt 9801 1080
    Het 15 2
E292V
    Wt 9706 1063
    Het 110 19
P766S
    Wt 9695 1067
    Het 121 15
R1474W
    Wt 9636 1064
    Het 180 18
SP-B121ins2
    Wt 10427 1209
    Het 21 5
α1-antitrypsin
    MM 8082 927
    ZZ 6 3
Multi variate adjusted
0.1 1 10
Figure 2 Risk of COPD according to ATP binding cassette member 3 (ABCA3) genotype in the Copenhagen City Heart Study. COPD was
FEV1/FVC < 0.7 and FEV1 < 80% of predicted. Values represent odds ratios and 95% confidence intervals. Multivariate adjusted models allowed for
age, sex, and packyears. Risk of COPD according to surfactant protein-B 121ins2 heterozygosity and α1-antitrysin ZZ homozygosity serve as positive
controls. Numbers of individuals with surfactant protein-B 121ins2 heterozygosity and α1-antitrypsin ZZ homozygosity differ slightly from the
number of individuals with ABCA3 genotypes due to different number of study subjects available for analysis within the study period.
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tion of smokers and amount of tobacco smoked were
lower in the Copenhagen General Population Study as
compared with the Copenhagen City Heart Study [22].
This is likely due to the declining number of smokers in
the Danish population over the past decades.
Results on pulmonary function are displayed in Additional
file 8. We found that FEV1 % predicted, FVC % predicted,
and FEV1/FVC did not differ in E292V heterozygotes vs
wildtypes (p≥0.67), whereas FEV1 % predicted was reduced
in the positive controls, surfactant protein-B 121ins2 hetero-
zygotes and α1-antitrypsin ZZ homozygotes. In accordance
with the results on pulmonary function, the multivariate
adjusted odds ratio for COPD was not increased in E292V
heterozygotes compared with wildtypes (odds ratio 1.10
(0.83-1.46)), while surfactant protein-B 121ins2 heterozy-
gotes and α1-antitrypsin ZZ homozygotes had increasedTable 1 Characteristics of participants in the Copenhagen Cit
Study according to E292V genotype
Copenhagen City Heart Stud
Wildtypes E292V heterozygotes
N 9,706 110
Women, % 5,374 (55) 60 (55)
Age, yrs 58 (44-69) 57 (45-67)
Eversmokers, % 76 77
Packyears of tobacco smoked 25 (11-40) 25 (13-40)
Values represent number, median (interquartile range), or percent. P-values are byodds ratios for COPD of 2.8 (1.0-8.1) and 6.6 (1.7-26) (Add-
itional file 9).
Pulmonary function and COPD by ABCA3 E292V in the
Copenhagen City Heart Study and Copenhagen General
Population Study combined
Finally, to maximize our statistical power, we combined
the Copenhagen City Heart Study and Copenhagen Gen-
eral Population Study. In this analysis, we found that
FEV1 % predicted, FVC % predicted, and FEV1/FVC did
not differ in E292V heterozygotes vs wildtypes (p≥0.28),
whereas FEV1 % predicted was reduced in the positive
controls, surfactant protein-B 121ins2 heterozygotes and
α1-antitrysin ZZ homozygotes (figure 3). We also strati-
fied our data for smoking status, as did our previous
study of surfactant protein-B 121ins2 as a risk factor in
COPD [12], but found no significant differences in lungy Heart Study and the Copenhagen General Population
y Copenhagen General Population Study
p-value Wildtypes E292V heterozygotes p-value
53,685 710
0.86 29,756 (55) 394 (55) 0.97
0.57 60 (50-70) 59 (49-69) 0.20
0.72 60 59 0.40
0.72 17 (6-31) 15 (6-30) 0.44
Pearson’s χ2 test or Wilcoxon rank-sum test.
60 80 100
Genotype N FEV1 % predicted P FVC % predicted P FEV1/FVC P
All
E292V
    Wt 63391
    Het 820 0.28 0.40 0.60
SPB121ins2
    Wt 46409
    Het 83 0.02 0.07 0.11
α1 antitrypsin
    MM 40066
    ZZ 19 0.0008 0.1 9 0.0009
Never smoker
E292V
    Wt 23738
    Het 319 0.81 0.99 0.53
SPB121ins2
    Wt 16248
    Het 36 0.60 0.50 0.70
α1 antitrypsin
    MM 14022
    ZZ 9 0.43 0.82 0.67
Smoker
E292V
    Wt 39653
    Het 501 0.11 0.26 0.19
SPB121ins2
    Wt 30175
    Het 47 0.0008 0.01 0.00007
α1 antitrypsin
    MM 26044
    ZZ 10 0.0001 0.10 0.0001
60 80 100 0.6 0.8
Figure 3 Lung function according to ATP binding cassette member 3 (ABCA3) E292V, surfactant protein-B 121ins2, and α1-antitrypsin
ZZ genotypes in the Copenhagen City Heart Study and Copenhagen General Population Study combined, stratified for smoking
status. Values are mean and standard error. P-values are by Student’s t-test. Lung function according to surfactant protein-B 121ins2
heterozygosity and α1-antitrysin ZZ homozygosity serve as positive controls. Numbers of individuals with surfactant protein-B 121ins2
heterozygosity and α1-antitrypsin ZZ homozygosity differ slightly from the number of individuals with an ABCA3 E292V genotype due to different
number of study subjects available for analysis within the study period.
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protein-B 121ins2 heterozygotes had 9% reduced FEV1 %
predicted (p = 0.0008), 6% reduced FVC % predicted
(p = 0.01), and 6% reduced FEV1/FVC (p = 0.00007)
compared with wildtypes. Corresponding lung function
reductions for α1-antitrypsin ZZ homozygotes were 24%
(p = 0.0001), 8% (p = 0.10), and 19% (p = 0.0001). Among
nonsmokers, lung function did not differ in surfactant
protein-B 121ins2 heterozygotes and α1-antitrysin ZZ
homozygotes versus wildtypes (p≥0.43).
Individuals heterozygous for E292V had multivariate
adjusted odds ratios for COPD of 1.2 (0.96-1.57) among all
subjects, of 1.1 (0.6-2.1) among nonsmokers, and of 1.2
(0.95-1.63) among smokers, respectively, compared with
wildtypes (Figure 4). Corresponding odds ratios for surfac-
tant protein-B 121ins2 heterozygotes were 2.1 (1.7-3.8),
1.4 (0.3-5.9), and 2.4 (1.2-4.8), and for α1-antitrypsin ZZ
homozygotes 6.0 (2.2-16), 4.8 (0.3-40), and 11 (3.1-42).
These results were in accordance with the results observedfor lung function for these gene variants. We had 80%
power to exclude odds ratios for COPD for E292V hetero-
zygotes of 1.3, for surfactant protein-B 121ins2 heterozy-
gotes of 2.1, and for α1-antitrypsin ZZ homozygotes of 4.0.
Discussion
To test whether individuals heterozygous for ABCA3 var-
iants have reduced lung function and increased risk of
COPD in the general population, we screened 760 indivi-
duals with extreme lung phenotypes for genetic varia-
tions in the ABCA3 gene and identified three novel
(H86Y, A320T, A1086D) and four previously described
variations (E292V, P766S, S1262G, R1474W). We next
genotyped the entire Copenhagen City Heart Study (n =
10,604) to assess the clinical importance of these seven
mutations. We found that E292V heterozygotes had
reduced lung function and increased risk of COPD,
whereas the novel A1086 mutation was associated with
increased lung function. To validate the findings for
N Events N Events N Events
E292V
    Wt 63391 5168 23738 726 39653 4442
    Het 820 75 319 10 501 65
SP-B 121ins2
    Wt 46423 4735 16248 660 30175 4075
    Het 83 15 36 2 47 13
α1-antitrypsin
    MM 40066 3588 14022 454 26044 3134








Figure 4 Risk of COPD according to ATP binding cassette member 3 (ABCA3) E292V, surfactant protein-B 121ins2, and α1-antitrypsin ZZ
genotypes in the Copenhagen City Heart Study and Copenhagen General Population Study combined, stratified for smoking status. COPD
was FEV1/FVC < 0.7 and FEV1 < 80% of predicted. Values represent odds ratios and 95% confidence intervals. Logistic regression models allowed for
age, sex, and packyears. Numbers of individuals with surfactant protein-B 121ins2 heterozygosity and α1-antitrypsin ZZ homozygosity differ slightly from
the number of individuals with an ABCA3 E292V genotype due to different number of study subjects available for analysis within the study period.
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from the Copenhagen General Population Study. In this
larger cohort, and in the two study cohorts combined, we
found that E292V heterozygotes did not have reduced
lung function or increased risk of COPD. Supporting this
overall negative result, the estimates for the positive con-
trols, surfactant protein-B 121ins2 heterozygotes and α1-
antitrypsin ZZ homozygotes, were relatively stable
throughout the studies and there was no evidence of se-
lection bias against E292V in any of the two cohorts.
The phenotype in E292V carriers was previously
reported to range from minimal changes on lung biopsy
and no symptoms to severe fatal lung disease [8,9]. It is
thus possible that E292V may cause lung disease in cer-
tain contexts or subgroups of individuals, e.g. when add-
itional impairments of surfactant function are present,
leaving the average carrier unaffected. Tobacco smoking
[23] and unidentified mutations in surfactant protein-C
[24,25], ABCA3 [26], and surfactant protein-B could be
risk factors of additionally impaired surfactant function
in E292V heterozygotes; although the latter risk factors
are probably less prevalent in the general population as
compared with tobacco smoking. Because participants in
the Copenhagen City Heart Study smoked more tobacco
than participants from the Copenhagen General Popula-
tion Study we speculate that the difference in smoking
habits between the two cohorts could partly contribute
to the different results observed for E292V in the two
cohorts. When statistical power, however, was maxi-
mised using the Copenhagen General Population Study
or the two studies combined, E292V heterozygotes didnot differ from wildtypes in lung function or COPD risk.
This is an important finding as 1.3% in the Danish gen-
eral population has partially reduced ABCA3 function
due to E292V, and since this variant has been linked pre-
viously with severe chronic lung disease in heterozygous
and compound heterozygous E292V carriers [8-10].
Besides E292V, we identified six other variants of po-
tential relevance to ABCA3 function. However, none of
these mutations were associated with lung function
or risk of COPD, except for the novel A1086D muta-
tion. This variant associated with increases in FEV1 %
predicted and FVC % predicted. However, the small
number of A1086D heterozygotes (n = 4) makes this
finding highly insecure. In addition, if correction for
multiple comparisons was performed none of the results
for A1086D and E292V in the Copenhagen City Heart
Study would be of statistical significance. The second
novel mutation, H86Y, is situated in the first extracellu-
lar loop of ABCA3. Another mutation in this loop,
L101P, has been shown to affect ABCA3 protein folding
leading to retention of ABCA3 in the endoplasmatic
reticulum and subsequent ER stress and apoptosis
[27,28], however individuals heterozygous for the H86Y
mutation appeared asymptomatic in this study. The
third novel mutation, A320T, resides in the transmem-
brane helix domain of ABCA3 and did also not associate
with lung function or COPD. Finally, the previously
described R1474W mutation may seem particularly
interesting as this mutation is situated within the con-
served nucleotide binding domain which is important
for binding of ATP [19]. However, no association with
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R1474W heterozygosity.
The results of the combined studies showed that
surfactant protein-B 121ins2 heterozygotes had reduced
FEV1 % predicted and increased risk of COPD. This ob-
servation is novel and extends our previous finding of
reduced lung function and elevated COPD risk among
121ins2 heterozygous smokers [12]. Supporting an asso-
ciation between surfactant protein-B and COPD, type II
pneumocytes have been proposed to play important roles
in COPD development [29]. In line with this, surfactant
protein-A [30] and surfactant protein-D [31,32] may be
involved in smoking-related lung diseases, and cystic
changes and paraseptal emphysema have been previously
reported in interstitial lung disease associated with muta-
tions in the surfactant protein-C gene [33,34]. The reduc-
tion in lung function and elevated risk of COPD in
surfactant protein-B 121ins2 heterozygotes in this study
was still driven by an effect among smokers, while non-
smokers were unaffected (Figures 3 and 4). Future large
epidemiological studies are needed to confirm these
results and to further assess whether surfactant protein-B
121ins2 combined with other genetic risk factors may be
clinically useful in the prediction of COPD. A recent
study has demonstrated that combinations of gene var-
iants may associate with up to a 4.7-fold increased COPD
risk [35], and many more gene variants related to COPD
could be identified and/or implemented in COPD predic-
tions in the future [36-40].
Some degree of misclassification of COPD was pos-
sible, since we used prebronchodilator values for lung
function to define the disease. However, if the COPD def-
inition excluded asthmatics the results were congruent.
All participants in this study are Danish whites and of
Danish descent, not reflecting today’s ethnic pattern in
the general population. Although this eliminates any
blurring due to ethnic heterogeneity of the study popula-
tion, our results may apply to Caucasians only. Bias
caused by investigator knowledge of disease or risk factor
status seems unlikely because our sample was selected
from the general population and because genotyping of
our sample was performed without investigator know-
ledge of disease status or lung function test results.Conclusions
We found with significant statistical power that ABCA3
E292V heterozygotes do not have reduced lung function
or increased risk of COPD in the general population.
This is an important finding as 1.3% in the Danish gen-
eral population has partially reduced ABCA3 function
due to E292V and since this variant has been linked
previously with severe chronic lung disease in E292V
heterozygotes and compound heterozygotes.Additional files
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